Scisparc

Scisparc Net Debt / EBITDA

The Net Debt to EBITDA of Scisparc (SPRC) as of Oct 16, 2026 is 0.48. In the previous year, Net Debt to EBITDA was 0.27 — a change of 75.68% (higher).

Net Debt / EBITDA

0.48

YoY

75.68%

Last updated:

Net Debt to EBITDA of Scisparc is 2025 0.48 . Net Debt to EBITDA of Scisparc was 2024 0.27 . It decreases by 75.68% higher compared to the previous year.

The Scisparc Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2018
-0.04 USD
Jan 1, 2019
0.09 USD
Jan 1, 2020
0.45 USD
Jan 1, 2021
1.10 USD
Jan 1, 2022
0.48 USD
Jan 1, 2023
0.87 USD
Jan 1, 2024
0.27 USD
Jan 1, 2025
0.48 USD
The Scisparc Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
0.48+75.68%
0.27-68.26%
0.87+80.20%
0.48-56.49%
1.10+145.59%
0.45+399.34%
0.09-341.03%
-0.04-101.21%
3.09+177.40%
1.12+27.31%
0.88-59.59%
2.17—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scisparc Stock analysis

What does Scisparc do? Scisparc Ltd., listed under the ticker SPRC with ISIN IL0010951403, is a biotechnology company headquartered in Tel Aviv-Yafo, Israel. The company operates in the healthcare sector and has a workforce of three employees. Scisparc Ltd. went public through an IPO on December 22, 2021. Its website is https://scisparc.com/. The company is engaged in the development of pharmaceutical products based on cannabinoid technologies, focusing on repurposing dronabinol for various medical conditions. Specific drug development programs include THX-110 for Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for infectious diseases; and THX-160 for pain treatment. Scisparc Ltd. is a clinical stage pharmaceutical company, indicating its focus on advancing drug candidates through clinical trials toward potential regulatory approval and commercialization. The company's activities are centered around leveraging cannabinoid-based approaches to address unmet medical needs in multiple therapeutic areas. Scisparc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scisparc stock

Net Debt to EBITDA of Scisparc is 0.48 in 2025.

Net Debt to EBITDA of Scisparc changed from 0.27 to 0.48, representing a 75.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Scisparc since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Scisparc with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Scisparc

All Key Metrics — Scisparc